Zadaxin

Zadaxin®

Thymosin alpha 1, see there.
References in periodicals archive ?
An increase of $4.4 million was attributed to an increase in volume of 12%, an increase of $3.3 million was attributed to revenues from sales generated in the first quarter of 2017 but recognized only in the second quarter of 2017, which were above the reference tender price under a provision in the agreement with the Company's China distributor, a decrease of $0.8 million was attributed to ZADAXIN products sold in the second quarter that the Company estimates will be ultimately sold at prices below the reference tender price under a provision in the agreement with the Company's China distributor, and a decrease of $1.8 million was attributed to an unfavorable exchange rate since last year.
Its lead product Zadaxin (thymalfasin), marketed since 1996, has been approved in over 30 countries for indications including hepatitis B, hepatitis C, and some types of cancers, as well as an immune system enhancer.
The company's proprietary lead product, Zadaxin (thymalfasin), is approved in over 30 countries and may be used for the treatment of hepatitis B, hepatitis C, and certain cancers, and as an immune system enhancer, according to the local regulatory approvals.
ZADAXIN, [N.sup.[alpha]]-terminal acetylated T[alpha]1 produced by total chemical synthesis energizes the immune response, helping patients to battle invasive cancers and secondary infections.
The company's ZADAXIN (thymalfasin) is approved in more than 30 countries for use in hepatitis B and C, as a vaccine adjuvant and to treat certain cancers.
SciClone Pharmaceuticals Inc (Foster City CA) posted a quarterly profit that beat market estimates, driven by strong sales of its hepatitis B treatment Zadaxin in China and lower research and development expenses.
Thymalfasin (Zadaxin), for example, is a synthetic version of a peptide (a small protein) originating from the thymus gland (which produces immune factors called T-cells).
SciClone's ZADAXIN is currently being evaluated in several clinical trials, including two phase 3 hepatitis C clinical trials in the U.S., a completed phase 3 hepatitis B clinical trial in Japan, a phase 2 malignant melanoma clinical trial in Europe, two phase 2 liver cancer pilot studies in the U.S., a hepatitis C triple therapy open-label clinical trial in Mexico, and a hepatitis B combination therapy trial in Taiwan.
SciClone's Zadaxin (Thymosin alfa-1; thymalfasin) is a synthetic peptide, derived from human thymus gland extracts, that modulates immune responses.
The clinical trial will compare the triple combination therapy of Zadaxin, peginterferon alfa-2a and ribavirin to placebo, peginterferon alfa-2a and rebavirin to evaluate the benefit of adding Zadaxin to current therapy for hepatitis C patients who have failed to respond to previous treatment.
SCV-07 has shown the capability to stimulate the immune system in a manner similar to SciClone's lead product ZADAXIN, and SCV-07 may have a significant additional benefit of being orally available.
SciClone Pharmaceuticals (San Mateo, CA; 650-358-3437) announced that the United States Patent and Trademark Office has issued a Notice of Allowance for use of the company's lead drug, ZADAXIN plus lamivudine and famciclovir for the treatment of hepatitis B.